EUVIMEDEUVIMED entdecken
Open Access

Clinical features of PPP2 syndrome type R5D (Jordan's syndrome) to support standardization of care

Alexis D Levine iD, Wendy K Chung iD

Molecular Case Studies · 2023

DOI: 10.1101/mcs.a006285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Case Studies, 2023. Verfasst von Alexis D Levine und 1 weiteren Autor:innen. Beteiligte Einrichtung: New York Medical College, Valhalla, New York 10595, USA; alevine220@gmail.com. Hauptthemen laut MEDLINE: Intellectual Disability, Neurodevelopmental Disorders, Autistic Disorder. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PPP2 syndrome type R5D, or Jordan's syndrome, is a neurodevelopmental disorder caused by pathogenic missense variants in PPP2R5D , a β-subunit of the Protein Phosphatase 2A (PP2A). The condition is characterized by global developmental delays, seizures, macrocephaly, ophthalmological abnormalities, hypotonia, attention disorder, social and sensory challenges often associated with autism, disordered sleep, and feeding difficulties. Among affected individuals, there is a broad spectrum of severity, and each person only has a subset of all associated symptoms. Some, but not all, of the clinical variability is due to differences in the PPP2R5D genotype. These suggested clinical care guidelines for the evaluation and treatment of individuals with PPP2 syndrome type R5D are based on data from 100 individuals reported in the literature and from an ongoing natural history study. As more data are available, particularly for adults and regarding treatment response, we anticipate that revisions to these guidelines will be made.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intellectual DisabilityNeurodevelopmental DisordersAutistic DisorderAdultHumansJordanSyndromeReference StandardsProtein Phosphatase 2

Stichwörter der Autor:innen

attention deficit hyperactivity disorderautismdelayed fine motor developmentdelayed gross motor developmentintellectual disabilitymacrocephaly at birthmoderatemoderate global developmental delaypostnatal macrocephalysleep disturbance

Substanzen

PPP2R5D protein, humanProtein Phosphatase 2

Autor:innen und Institutionen

  • New York Medical College, Valhalla, New York 10595, USA; alevine220@gmail.com.
  • Columbia University, New York, New York 10032, USA.

ORCID-Profile: Alexis D Levine, Wendy K Chung

Zitieren

APA

Levine, A. D., & Chung, W. K. (2023). Clinical features of PPP2 syndrome type R5D (Jordan's syndrome) to support standardization of care. Molecular Case Studies. https://doi.org/10.1101/mcs.a006285

Vancouver

Levine AD, Chung WK. Clinical features of PPP2 syndrome type R5D (Jordan's syndrome) to support standardization of care. Molecular Case Studies. 2023. doi:10.1101/mcs.a006285

BibTeX
@article{Levine2023,
  author = {Levine, Alexis D and Chung, Wendy K},
  title = {Clinical features of PPP2 syndrome type R5D (Jordan's syndrome) to support standardization of care},
  journal = {Molecular Case Studies},
  year = {2023},
  doi = {10.1101/mcs.a006285}
}
Kostenlos starten →